Actinogen Medical Ltd
ASX:ACW

Watchlist Manager
Actinogen Medical Ltd Logo
Actinogen Medical Ltd
ASX:ACW
Watchlist
Price: 0.049 AUD 2.08% Market Closed
Market Cap: AU$155.9m

Net Margin

-2 149.8%
Current
Improving
by 1 699.7%
vs 3-y average of -3 849.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-2 149.8%
=
Net Income
AU$-14.7m
/
Revenue
AU$685.3k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-2 149.8%
=
Net Income
AU$-14.7m
/
Revenue
AU$685.3k

Peer Comparison

Country Company Market Cap Net
Margin
AU
Actinogen Medical Ltd
ASX:ACW
155.7m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44.1B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

Lower than 80% of companies in Australia
Percentile
20th
Based on 4 004 companies
20th percentile
-2 149.8%
Low
-16 177 900% — -544.7%
Typical Range
-544.7% — 3.1%
High
3.1% — 3 174 540%
Distribution Statistics
Australia
Min -16 177 900%
30th Percentile -544.7%
Median -27.7%
70th Percentile 3.1%
Max 3 174 540%

Actinogen Medical Ltd
Glance View

Market Cap
155.9m AUD
Industry
Biotechnology

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in developing treatment for cognitive impairment associated with neurological diseases of raised cortisol levels inside brain cells. The firm's lead drug candidate, Xanamem, has been designed to block the production of cortisol the stress hormone in the brain. Xanamem is a unique inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the central nervous system. The company is an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s Disease, linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in neuropsychiatric diseases. The firm focuses on developing Phase II clinical trial evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer’s disease.

ACW Intrinsic Value
0.001 AUD
Overvaluation 97%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-2 149.8%
=
Net Income
AU$-14.7m
/
Revenue
AU$685.3k
What is Actinogen Medical Ltd's current Net Margin?

The current Net Margin for Actinogen Medical Ltd is -2 149.8%, which is above its 3-year median of -3 849.5%.

How has Net Margin changed over time?

Over the last 3 years, Actinogen Medical Ltd’s Net Margin has increased from -23 108% to -2 149.8%. During this period, it reached a low of -23 108% on May 30, 2022 and a high of -2 149.8% on Jul 30, 2025.

Back to Top